Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA
BG-12, an investigational oral therapy, shows promising results in reducing inflammation and neuroprotection in patients with relapsing-remitting multiple sclerosis (RRMS) and rheumatoid arthritis (RA). The compound has activated the Nrf2 pathway, which defends against oxidative-stress induced neuronal death and supports myelin integrity.